FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation

On March 30, 2017, the U.S. Food and Drug Administration (FDA) approved osimertinib for the treatment of patients with metastatic, epidermal growth factor receptor (EGFR) T790M mutation‐positive, non‐small cell lung cancer (NSCLC), as detected by an FDA‐approved test, whose disease has progressed fo...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncologist
Auteurs principaux: Odogwu, Lauretta, Mathieu, Luckson, Goldberg, Kirsten B., Blumenthal, Gideon M., Larkins, Erin, Fiero, Mallorie H., Rodriguez, Lisa, Bijwaard, Karen, Lee, Eunice Y., Philip, Reena, Fan, Ingrid, Donoghue, Martha, Keegan, Patricia, McKee, Amy, Pazdur, Richard
Format: Artigo
Langue:Inglês
Publié: AlphaMed Press 2017
Sujets:
Regulatory Issues: FDA
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5905690/
https://ncbi.nlm.nih.gov/pubmed/29242281
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0425
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires